BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buu MC, Sanders LM, Mayo JA, Milla CE, Wise PH. Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California. Chest 2016;149:380-9. [PMID: 26086984 DOI: 10.1378/chest.14-2189] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 . Spectrum of gene variants linked to cystic fibrosis in nonwhites: Research finds certain screening panels may be inadequate. Am J Med Genet A 2016;170A:822-3. [PMID: 27001910 DOI: 10.1002/ajmg.a.37615] [Reference Citation Analysis]
2 Mcgarry ME, Gibb ER, Oates GR, Schechter MS. Left Behind: The Potential Impact of CFTR Modulators on Racial and Ethnic Disparities in Cystic Fibrosis. Paediatric Respiratory Reviews 2021. [DOI: 10.1016/j.prrv.2021.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Szczesniak RD, Li D, Su W, Brokamp C, Pestian J, Seid M, Clancy JP. Phenotypes of Rapid Cystic Fibrosis Lung Disease Progression during Adolescence and Young Adulthood. Am J Respir Crit Care Med 2017;196:471-8. [PMID: 28410569 DOI: 10.1164/rccm.201612-2574OC] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
4 DiMango E, Simpson K, Menten E, Keating C, Fan W, Leu CS. Health Disparities among adults cared for at an urban cystic fibrosis program. Orphanet J Rare Dis 2021;16:332. [PMID: 34332588 DOI: 10.1186/s13023-021-01965-4] [Reference Citation Analysis]
5 Russell CJ, Simon TD, Mamey MR, Newth CJL, Neely MN. Pseudomonas aeruginosa and post-tracheotomy bacterial respiratory tract infection readmissions. Pediatr Pulmonol 2017;52:1212-8. [PMID: 28440922 DOI: 10.1002/ppul.23716] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
6 Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Burgel P, Tullis E, Castaños C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-hamblett N, Kashirskaya N, Kerem E, Mathew JL, Mckone EF, Naehrlich L, Nasr SZ, Oates GR, O'neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F. The future of cystic fibrosis care: a global perspective. The Lancet Respiratory Medicine 2020;8:65-124. [DOI: 10.1016/s2213-2600(19)30337-6] [Cited by in Crossref: 183] [Cited by in F6Publishing: 82] [Article Influence: 91.5] [Reference Citation Analysis]
7 Rho J, Ahn C, Gao A, Sawicki GS, Keller A, Jain R. Disparities in Mortality of Hispanic Patients with Cystic Fibrosis in the United States. A National and Regional Cohort Study. Am J Respir Crit Care Med 2018;198:1055-63. [PMID: 29742360 DOI: 10.1164/rccm.201711-2357OC] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 8.3] [Reference Citation Analysis]
8 Kerem E, Cohen-cymberknoh M. Disparities in Cystic Fibrosis Care and Outcome. Chest 2016;149:298-300. [DOI: 10.1016/j.chest.2015.08.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
9 Thakur N, Lovinsky-Desir S, Appell D, Bime C, Castro L, Celedón JC, Ferreira J, George M, Mageto Y, Mainous Iii AG, Pakhale S, Riekert KA, Roman J, Ruvalcaba E, Sharma S, Shete P, Wisnivesky JP, Holguin F. Enhancing Recruitment and Retention of Minority Populations for Clinical Research in Pulmonary, Critical Care, and Sleep Medicine: An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med 2021;204:e26-50. [PMID: 34347574 DOI: 10.1164/rccm.202105-1210ST] [Reference Citation Analysis]
10 Kerem E. Cystic fibrosis: Priorities and progress for future therapies. Paediatr Respir Rev 2017;24:14-6. [PMID: 28697970 DOI: 10.1016/j.prrv.2017.06.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
11 Oates GR, Schechter MS. Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies. Expert Rev Respir Med 2022;:1-14. [PMID: 35705523 DOI: 10.1080/17476348.2022.2090928] [Reference Citation Analysis]
12 Golembiewski E, Allen KS, Blackmon AM, Hinrichs RJ, Vest JR. Combining Nonclinical Determinants of Health and Clinical Data for Research and Evaluation: Rapid Review. JMIR Public Health Surveill 2019;5:e12846. [PMID: 31593550 DOI: 10.2196/12846] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 McGarry ME, Williams WA 2nd, McColley SA. The demographics of adverse outcomes in cystic fibrosis. Pediatr Pulmonol 2019;54 Suppl 3:S74-83. [PMID: 31715087 DOI: 10.1002/ppul.24434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
14 Chin M, Earlam K, Aaron SD. Survival in Cystic Fibrosis: Trends, Clinical Factors, and Prediction Models. Pediatric Allergy, Immunology, and Pulmonology 2015;28:244-9. [DOI: 10.1089/ped.2015.0531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
15 Lahiri T, Sullivan JS. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy. Pediatr Pulmonol 2021. [PMID: 34473419 DOI: 10.1002/ppul.25660] [Reference Citation Analysis]
16 Andrade A, Pizarro ME. Medicina de precisión en fibrosis quística. Revista Médica Clínica Las Condes 2022;33:44-50. [DOI: 10.1016/j.rmclc.2021.12.003] [Reference Citation Analysis]
17 Russell JK, Strodl E, Kavanagh DJ. Correlates of distress in young people with cystic fibrosis: the role of self-efficacy and metacognitive beliefs. Psychol Health 2020;:1-17. [PMID: 33370209 DOI: 10.1080/08870446.2020.1861280] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 McGarry ME, Neuhaus JM, Nielson DW, Burchard E, Ly NP. Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis. Pediatr Pulmonol 2017;52:1550-7. [PMID: 29082671 DOI: 10.1002/ppul.23884] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
19 McGarry ME, Huang CY, Nielson DW, Ly NP. Early acquisition and conversion of Pseudomonas aeruginosa in Hispanic youth with cystic fibrosis in the United States. J Cyst Fibros 2021;20:424-31. [PMID: 33162303 DOI: 10.1016/j.jcf.2020.10.002] [Reference Citation Analysis]
20 Perez AA, Leard LE. What's in a name: The importance of lung transplant at Cystic Fibrosis Foundation Accredited Care Centers for patients with Cystic Fibrosis. J Heart Lung Transplant 2021:S1053-2498(21)02612-7. [PMID: 34973873 DOI: 10.1016/j.healun.2021.11.015] [Reference Citation Analysis]
21 Savant AP, Mccolley SA. Cystic fibrosis year in review 2016. Pediatr Pulmonol 2017;52:1092-102. [DOI: 10.1002/ppul.23747] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
22 McGarry ME, McColley SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol 2021;56:1496-503. [PMID: 33470563 DOI: 10.1002/ppul.25285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
23 McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: Advances and challenges. Pediatr Pulmonol 2021. [PMID: 34672432 DOI: 10.1002/ppul.25733] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Chen L, Gong J, Matta E, Morrone K, Manwani D, Rastogi D, De A. Pulmonary disease burden in Hispanic and non-Hispanic children with sickle cell disease. Pediatr Pulmonol 2020;55:2064-73. [PMID: 32484996 DOI: 10.1002/ppul.24883] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Corriveau S, Sykes J, Stephenson AL. Cystic fibrosis survival: the changing epidemiology. Current Opinion in Pulmonary Medicine 2018;24:574-8. [DOI: 10.1097/mcp.0000000000000520] [Cited by in Crossref: 26] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
26 Li SS, Hayes D, Tobias JD, Morgan WJ, Tumin D. Health insurance and use of recommended routine care in adults with cystic fibrosis. Clin Respir J 2018;12:1981-8. [DOI: 10.1111/crj.12767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
27 Oates GR, Schechter MS. Socioeconomic status and health outcomes: cystic fibrosis as a model. Expert Review of Respiratory Medicine 2016;10:967-77. [DOI: 10.1080/17476348.2016.1196140] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
28 Williams WA 2nd, Jain M, Laguna TA, McColley SA. Preferences for disclosing adverse childhood experiences for children and adults with cystic fibrosis. Pediatr Pulmonol 2021;56:921-7. [PMID: 33369260 DOI: 10.1002/ppul.25243] [Reference Citation Analysis]
29 Dickinson KM, Psoter KJ, Riekert KA, Collaco JM. Association between insurance variability and early lung function in children with cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)01290-X. [PMID: 34175244 DOI: 10.1016/j.jcf.2021.06.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Sawicki GS, Van Brunt K, Booth J, Bailey E, Millar SJ, Konstan MW, Flume PA. Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation. J Cyst Fibros 2021:S1569-1993(21)01300-X. [PMID: 34289939 DOI: 10.1016/j.jcf.2021.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Buu MC, Milla CE. Tear Down This Wall: Diversity and Disparities in Cystic Fibrosis. Am J Respir Crit Care Med 2018;198:983-4. [DOI: 10.1164/rccm.201806-1076ed] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Goetz DM, Singh S. Respiratory System Disease. Pediatr Clin North Am 2016;63:637-59. [PMID: 27469180 DOI: 10.1016/j.pcl.2016.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
33 Rho J, Ahn C, Gao A, Keller A, Jain R. Evaluating Outcomes Disparities in the Hispanic Cystic Fibrosis Population: A Need for a National Analysis. Chest 2016;150:751-3. [PMID: 27613984 DOI: 10.1016/j.chest.2016.06.041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
34 Soe K, Gregoire-Bottex MM. A rare CFTR mutation associated with severe disease progression in a 10-year-old Hispanic patient. Clin Case Rep 2017;5:139-44. [PMID: 28174639 DOI: 10.1002/ccr3.764] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
35 Fink AK, Loeffler DR, Marshall BC, Goss CH, Morgan WJ. Data that empower: The success and promise of CF patient registries. Pediatr Pulmonol 2017;52:S44-51. [PMID: 28910520 DOI: 10.1002/ppul.23790] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
36 McGarry ME, Neuhaus JM, Nielson DW, Ly NP. Regional variations in longitudinal pulmonary function: A comparison of Hispanic and non-Hispanic subjects with cystic fibrosis in the United States. Pediatr Pulmonol 2019;54:1382-90. [PMID: 31144477 DOI: 10.1002/ppul.24377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
37 Farooq F, Mogayzel PJ, Lanzkron S, Haywood C, Strouse JJ. Comparison of US Federal and Foundation Funding of Research for Sickle Cell Disease and Cystic Fibrosis and Factors Associated With Research Productivity. JAMA Netw Open 2020;3:e201737. [DOI: 10.1001/jamanetworkopen.2020.1737] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
38 Sanders DB, Fink AK. Background and Epidemiology. Pediatr Clin North Am 2016;63:567-84. [PMID: 27469176 DOI: 10.1016/j.pcl.2016.04.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
39 Villaverde-Hueso A, Sánchez-Díaz G, Molina-Cabrero FJ, Gallego E, Posada de la Paz M, Alonso-Ferreira V. Mortality Due to Cystic Fibrosis over a 36-Year Period in Spain: Time Trends and Geographic Variations. Int J Environ Res Public Health 2019;16:E119. [PMID: 30621191 DOI: 10.3390/ijerph16010119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
40 Januska MN, Marx L, Walker PA, Berdella MN, Langfelder-Schwind E. The CFTR variant profile of Hispanic patients with cystic fibrosis: Impact on access to effective screening, diagnosis, and personalized medicine. J Genet Couns 2020;29:607-15. [PMID: 32227567 DOI: 10.1002/jgc4.1271] [Reference Citation Analysis]
41 Buu MC, Milla CE, Wise PH. Response. Chest 2016;150:753. [PMID: 27613985 DOI: 10.1016/j.chest.2016.07.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 McGarry ME, McColley SA. Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis. Ann Am Thorac Soc 2016;13:1721-5. [PMID: 27410177 DOI: 10.1513/AnnalsATS.201603-192BC] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
43 Dongarwar D, Garcia BY, Miller K, Salihu HM. Assessment of hospitalization rates, factors associated with hospitalization and in-patient mortality in pediatric patients with cystic fibrosis. J Natl Med Assoc 2021:S0027-9684(21)00190-5. [PMID: 34479733 DOI: 10.1016/j.jnma.2021.08.038] [Reference Citation Analysis]